Moreover, the allogeneic use of TCR T cells targeting TP53 mutations in a chemo-refractory breast cancer patient showed that autologous PBLs engineered with R175H-TCR at 6 weeks post-treatment infiltrated the patient’s tumor and had acquired a central memory phenotype with stem-like features, suggesting the longevity of these cells. The gene discussed is TP53; the disease is neoplasm.